We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Brazil has confirmed its pricing deal on US-based Abbott Laboratories' ARV Kaletra, according to the Reuters news agency. Last week, it was announced that the price per dose would fall more than 46% from US$1.17 to US$0.63.
It is reported that negotiations between German political parties SPD and the CDU, which have created a new coalition government, have impacted Germany's plans for healthcare reform.
The Chinese government will carry out a series of nationwide checks to ensure that recent drug price reductions introduced in September have been enforced.
Cadence Pharmaceuticals, Inc., a hospital-focused specialty pharmaceutical company, today announced the completion of a $25 million Series A preferred stock financing.
Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced that the Ontario Securities Commission (OSC) has advised that, in addition to the matters most recently disclosed in the Company's second quarter financial statements, the OSC is investigating the Company's revenue recognition for accounting purposes for each of the four quarters of 2002 and 2001, and related disclosure issues.
Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) announced that it has received notification from the Japanese Patent Office that patent coverage extending to XYOTAX(TM) (paclitaxel poliglumex) is allowable in Japan.
Dutch biotechnology company Crucell NV said that that Merck & Co Inc has exercised its option to use Crucell's PER.C6 production technology to develop an adenovirus-based vaccine against hepatitis C (HCV).
MorphoSys AG (Frankfurt Stock Exchange:MOR) (Prime Standard Segment:TecDAX) announced today the start of a further three therapeutic antibody programs within the scope of its collaboration with Schering AG, Germany (FSE:SCH) (NYSE:SHR).
Shares in SciGen more than doubled after the biopharmaceutical company announced a $US145 million-plus ($192 million) distribution deal into China for its Hepatitis-B vaccine, its first foray into the country.